Amgen and UCB’s Evenity (romosozumab) Receive EC’s Approval to Treat Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture

Shots:

• The EC has granted MAA to Evenity for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture, following the CHMP’s positive opinion received in Oct’2019
• Evenity is the first osteoporosis therapy to be approved by EC since 2010 and the MAA will be valid in EU and EEA- EFTA states (Norway, Iceland and Liechtenstein)
• Evenity is a bone-forming mAb with a dual effect that increases bone formation and to a lesser extent reduces bone resorption (or bone loss) with its expected availability in EEA in H1’20

Click here to­ read full press release/ article | Ref: Amgen | Image: STAT News